A randomised, double blind, placebo controlled, parallel group, dose ranging study of GWP42004 as add on to metformin in the treatment of participants with Type 2 diabetes
Phase of Trial: Phase II
Latest Information Update: 20 Mar 2017
At a glance
- Drugs Tetrahydrocannabivarin 9 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors GW Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 02 Sep 2016 Status changed from active, no longer recruiting to completed.
- 07 Dec 2015 Status changed from recruiting to active, no longer recruiting, according to a GW Pharmaceuticals media release.